Drug treatment for spinal muscular atrophy type I.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.CD006281.pub3PMID 22161399
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Drug treatment for spinal muscular atrophy type I.

  2012cited by this paper
• Cochrane Handbook for Systematic Reviews of Interventions

  2010cited by this paper
• Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy

  2010cited by this paper
• Survival motor Neuron protein regulates apoptosis in anin vitro model of Spinal muscular atrophy

  2009cited by this paper
• Drug treatment for spinal muscular atrophy type I.

  2009cited by this paper
• Phase II Open Label Study of Valproic Acid in Spinal Muscular Atrophy

  2009cited by this paper
• Plastin 3 Is a Protective Modifier of Autosomal Recessive Spinal Muscular Atrophy

  2008cited by this paper
• Survival in SMA type I: a prospective analysis of 34 consecutive cases.

  2008cited by this paper
• Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic effect.

  2008cited by this paper
• Genetic conversion of an SMN2 gene to SMN1: a novel approach to the treatment of spinal muscular atrophy.

  2008cited by this paper
• Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy.

  2008cited by this paper
• Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy.

  2008cited by this paper
• Spinal muscular atrophy.

  2008cited by this paper
• Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy.

  2008cited by this paper
• A natural history study of late onset spinal muscular atrophy types 3b and 4

  2008cited by this paper
• The use of mechanical ventilation is appropriate in children with genetically proven spinal muscular atrophy type 1: the motion for.

  2008cited by this paper
• The use of invasive ventilation is appropriate in children with genetically proven spinal muscular atrophy type 1: the motion against.

  2008cited by this paper
• The changing natural history of spinal muscular atrophy type 1

  2007cited by this paper
• Consensus Statement for Standard of Care in Spinal Muscular Atrophy

  2007cited by this paper
• Molecular Mechanisms of Spinal Muscular Atrophy

  2007cited by this paper
• A Randomized, Placebo-Controlled Trial of Creatine in Children With Spinal Muscular Atrophy

  2007cited by this paper
• Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

  2007cited by this paper
• SMN protects cells against mutant SOD1 toxicity by increasing chaperone activity.

  2007cited by this paper
• Spinal muscular atrophy and therapeutic prospects.

  2006cited by this paper
• Spinal muscular atrophy: from gene to therapy.

  2006cited by this paper
• Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2.

  2006cited by this paper
• Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number

  2006cited by this paper
• In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate

  2006cited by this paper
• 134th ENMC International Workshop: Outcome Measures and Treatment of Spinal Muscular Atrophy, 11-13 February 2005, Naarden, The Netherlands.

  2005cited by this paper
• Natural history of denervation in SMA: Relation to age, SMN2 copy number, and function

  2005cited by this paper
• Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis/motor neuron disease.

  2004cited by this paper
• Riluzole attenuates spinal muscular atrophy disease progression in a mouse model

  2003cited by this paper
• An outcome study of riluzole in amyotrophic lateral sclerosis

  2003cited by this paper
• A phase 1 trial of riluzole in spinal muscular atrophy.

  2003cited by this paper
• Role of Gabapentin in Spinal Muscular Atrophy

  2003cited by this paper
• Reliability of 4 outcome measures in pediatric spinal muscular atrophy.

  2003cited by this paper
• Spinal muscular atrophy.

  2002cited by this paper
• Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy.

  2002cited by this paper
• Correlation between SMN2 copy number and clinical phenotype of spinal muscular atrophy: three SMN2 copies fail to rescue some patients from the disease severity

  2002cited by this paper
• Spinal muscular atrophy: Recent advances and future prospects

  2002cited by this paper
• 90th ENMC international workshop: European Spinal Muscular Atrophy Randomised Trial (EuroSMART) 9-10 February 2001, Naarden, The Netherlands.

  2002cited by this paper
• Spinal muscular atrophies.

  2002cited by this paper
• Muscle strength and motor function in children and adolescents with spinal muscular atrophy II and III.

  2001cited by this paper
• Homozygous deletion of the survival motor neuron 2 gene is a prognostic factor in sporadic ALS

  2001cited by this paper
• A placebo-controlled trial of gabapentin in spinal muscular atrophy.

  2001cited by this paper
• [From gene to disease; 'survival' motor neuron protein and hereditary proximal spinal muscle atrophy].

  2001cited by this paper
• An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA)

  2000cited by this paper
• The role of SMN in spinal muscular atrophy

  2000cited by this paper
• Spinal muscular atrophy: molecular pathophysiology.

  1999cited by this paper
• 59th ENMC International Workshop: Spinal Muscular Atrophies: recent progress and revised diagnostic criteria 17-19 April 1998, Soestduinen, The Netherlands.

  1999cited by this paper
• Spinal muscular atrophy

  1999influential reference
• A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy.

  1999cited by this paper
• The role of the SMN gene in proximal spinal muscular atrophy.

  1998cited by this paper
• A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing.

  1998cited by this paper
• SMN oligomerization defect correlates with spinal muscular atrophy severity

  1998cited by this paper
• An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole.

  1998cited by this paper
• Intragenic telSMN mutations: frequency, distribution, evidence of a founder effect, and modification of the spinal muscular atrophy phenotype by cenSMN copy number.

  1998cited by this paper
• Spinal Muscular Atrophy

  1998cited by this paper
• A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients.

  1997cited by this paper
• Correlation between severity and SMN protein level in spinal muscular atrophy

  1997cited by this paper
• Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis.

  1996cited by this paper
• Clinical trials of riluzole in patients with ALS

  1996cited by this paper
• Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.

  1996cited by this paper
• A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group.

  1996cited by this paper
• Function changes in spinal muscular atrophy II and III

  1996cited by this paper
• The neurobiology of childhood spinal muscular atrophy.

  1996cited by this paper
• A double‐blind placebo‐controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis

  1996cited by this paper
• Constitutive muscular abnormalities in culture in spinal muscular atrophy.

  1995cited by this paper
• Chaos in the classification of SMA: a possible resolution.

  1995cited by this paper
• Possible strategies for treatment of SMA patients: a neurobiologist's view.

  1995cited by this paper
• Identification and characterization of a spinal muscular atrophy-determining gene

  1995cited by this paper
• Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications.

  1995cited by this paper
• Deletions of the survival motor neuron gene in unaffected siblings of patients with spinal muscular atrophy.

  1995cited by this paper
• Efficacy of Thyrotropin-Releasing Hormone in the Treatment of Spinal Muscular Atrophy

  1994cited by this paper
• The natural history of type I (severe) spinal muscular atrophy.

  1994cited by this paper
• A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.

  1994cited by this paper
• De novo and inherited deletions of the 5q13 region in spinal muscular atrophies.

  1994cited by this paper
• Prospective study of spinal muscular atrophy before age 6 years. DCN/SMA Group.

  1993cited by this paper
• Spinal Muscular Atrophy: New Thoughts on the Pathogenesis and Classification Schema

  1992cited by this paper
• International SMA consortium meeting. (26-28 June 1992, Bonn, Germany).

  1992cited by this paper
• Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3.

  1990cited by this paper
• Gene for chronic proximal spinal muscular atrophies maps to chromosome 5q

  1990cited by this paper
• Mapping of acute (type I) spinal muscular atrophy to chromosome 5q12-q14. The French Spinal Muscular Atrophy Investigators.

  1990cited by this paper
• Genetic homogeneity between acute and chronic forms of spinal muscular atrophy

  1990cited by this paper

• Preliminary insights into RNA in CSF of pediatric SMA patients after 6 months of nusinersen

  2023cites this paper
• The importance of SMA screening tests in newborns – review

  2022cites this paper
• Nusinersen: A Review in 5q Spinal Muscular Atrophy

  2021cites this paper
• Nutritional, Gastrointestinal and Endo-Metabolic Challenges in the Management of Children with Spinal Muscular Atrophy Type 1

  2021cites this paper
• Muscle strength and motor function throughout life in a cross‐sectional cohort of 180 patients with spinal muscular atrophy types 1c–4

  2018cites this paper
• Treatment Advances in Spinal Muscular Atrophy

  2017cites this paper
• Therapeutic approaches for spinal muscular atrophy (SMA)

  2017cites this paper
• Study of Survival Motor Neuron protein regulation and the role of autophagy in Spinal Muscular Atrophy

  2015cites this paper
• Reliability and Validity of Outcome Measures of In-Hospital and At-Home Visits in a Randomized, Double-Blind, Placebo-Controlled Trial for Spinal Muscular Atrophy

  2014cites this paper
• Rasch analysis of clinical outcome measures in spinal muscular atrophy

  2014cites this paper
• Clinical Evaluation of a Neuroprotective Drug in Patients With Cervical Spondylotic Myelopathy Undergoing Surgical Treatment: Design and Rationale for the CSM-Protect Trial

  2013cites this paper
• Management of children with spinal muscular atrophy type 1 in Australia

  2013cites this paper
• The Neuroprotective Drug Riluzole Acts via Small Conductance Ca2+-Activated K+ Channels to Ameliorate Defects in Spinal Muscular Atrophy Models

  2013cites this paper
• Histone deacetylase inhibitors as potential treatment for spinal muscular atrophy

  2013cites this paper
• Drug treatment for spinal muscular atrophy type I.

  2012cites this paper
• Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585

  2012cites this paper
• Treatment of spinal muscolar atrophy with intrathecal mesenchymal cells.

  2012cites this paper
• Treatment Options in Motor Neuron Disease: Amyotrophic Lateral Sclerosis and Spinal Muscular Atrophy

  2012cites this paper
• Drug treatment for spinal muscular atrophy types II and III.

  2012cites this paper
• Neuromuscular disease and the pulmonologist

  2012cites this paper
• Drug treatment for spinal muscular atrophy type I.

  2012cites this paper
• Drug treatment for spinal muscular atrophy types II and III.

  2011cites this paper